BFC Planning’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$36.5K Buy
404
+29
+8% +$1.7K ﹤0.01% 1716
2026
Q2
$14.4K Hold
375
– – ﹤0.01% 2174
2026
Q1
$7.96K Sell
375
-8
-2% -$160 ﹤0.01% 2138
2025
Q4
$6.25K Buy
383
+293
+326% +$4.43K ﹤0.01% 2264
2025
Q3
$1.05K Hold
90
– – ﹤0.01% 2614
2025
Q2
$1.04K Sell
90
-13
-13% -$118 ﹤0.01% 2442
2025
Q1
$899 Buy
103
+13
+14% +$164 ﹤0.01% 2461
2024
Q4
$1.29K Hold
90
– – ﹤0.01% 2362
2024
Q3
$2.03K Buy
+90
New +$1.86K ﹤0.01% 2276

Other funds holding TXG

BFC Planning's TXG Position: Q3 2026 in Review

BFC Planning increased its 10x Genomics (TXG) stake by 7.7% in Q3 2026, buying an estimated $1.7K and bringing the position to 404 shares worth $36.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

BFC Planning first reported a position in TXG in Q3 2024 and has held it in 9 quarters since. 396 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • BFC Planning held 404 shares of 10x Genomics worth $36.5K as of Q3 2026.
  • BFC Planning bought 29 10x Genomics shares in Q3 2026, an estimated $1.7K.
  • 10x Genomics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1716 holding.
  • BFC Planning first reported a position in 10x Genomics in Q3 2024 and has held it in 9 quarters since.
  • 396 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.